434 related articles for article (PubMed ID: 24774505)
1. Adalimumab in the treatment of immune-mediated diseases.
Lapadula G; Marchesoni A; Armuzzi A; Blandizzi C; Caporali R; Chimenti S; Cimaz R; Cimino L; Gionchetti P; Girolomoni G; Lionetti P; Marcellusi A; Mennini FS; Salvarani C
Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):33-48. PubMed ID: 24774505
[TBL] [Abstract][Full Text] [Related]
2. anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.
Armuzzi A; Lionetti P; Blandizzi C; Caporali R; Chimenti S; Cimino L; Gionchetti P; Girolomoni G; Lapadula G; Marchesoni A; Marcellusi A; Mennini FS; Salvarani C; Cimaz R
Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):11-32. PubMed ID: 24774504
[TBL] [Abstract][Full Text] [Related]
3. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
Karampetsou MP; Liossis SN; Sfikakis PP
QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008
[TBL] [Abstract][Full Text] [Related]
4. The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases.
Blandizzi C; Gionchetti P; Armuzzi A; Caporali R; Chimenti S; Cimaz R; Cimino L; Lapadula G; Lionetti P; Marchesoni A; Marcellusi A; Mennini FS; Salvarani C; Girolomoni G
Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):1-10. PubMed ID: 24774503
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications.
Murdaca G; Colombo BM; Puppo F
Drugs Today (Barc); 2011 Apr; 47(4):277-88. PubMed ID: 21573251
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis.
Saraceno R; Bavetta M; Zangrilli A; Chiricozzi A; Potenza C; Chimenti S; Chimenti MS
Expert Opin Biol Ther; 2013 Sep; 13(9):1325-34. PubMed ID: 23930916
[TBL] [Abstract][Full Text] [Related]
7. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
9. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls.
Silva LC; Ortigosa LC; Benard G
Immunotherapy; 2010 Nov; 2(6):817-33. PubMed ID: 21091114
[TBL] [Abstract][Full Text] [Related]
10. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
Poddubnyy D; Rudwaleit M
Expert Opin Drug Saf; 2011 Jul; 10(4):655-73. PubMed ID: 21554150
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab in ulcerative colitis: ready for prime time.
Danese S
Dig Liver Dis; 2013 Jan; 45(1):8-13. PubMed ID: 22766323
[TBL] [Abstract][Full Text] [Related]
13. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.
Blackhouse G; Assasi N; Xie F; Marshall J; Irvine EJ; Gaebel K; Campbell K; Hopkins R; O'Reilly D; Tarride JE; Goeree R
J Crohns Colitis; 2012 Feb; 6(1):77-85. PubMed ID: 22261531
[TBL] [Abstract][Full Text] [Related]
14. [Anti-TNFalpha therapy in systemic autoimmune and/or inflammatory diseases].
Régent A; Mouthon L
Presse Med; 2009 May; 38(5):761-73. PubMed ID: 19349142
[TBL] [Abstract][Full Text] [Related]
15. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.
Schabert VF; Watson C; Gandra SR; Goodman S; Fox KM; Harrison DJ
J Med Econ; 2012; 15(2):264-75. PubMed ID: 22115327
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
Martín-de-Carpi J; Pociello N; Varea V
J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules.
Licastro F; Chiappelli M; Ianni M; Porcellini E
Int J Immunopathol Pharmacol; 2009; 22(3):567-72. PubMed ID: 19822073
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.
Burmester GR; Panaccione R; Gordon KB; McIlraith MJ; Lacerda AP
Ann Rheum Dis; 2013 Apr; 72(4):517-24. PubMed ID: 22562972
[TBL] [Abstract][Full Text] [Related]
19. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.
Fénix-Caballero S; Alegre-del Rey EJ; Castaño-Lara R; Puigventós-Latorre F; Borrero-Rubio JM; López-Vallejo JF
J Clin Pharm Ther; 2013 Aug; 38(4):286-93. PubMed ID: 23590560
[TBL] [Abstract][Full Text] [Related]
20. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
